REDUNDANCIES AND BUSINESS PLANNING: WHAT YOU NEED TO KNOW

Event date:

Recorded on 18 September 2020

With the tapering of Government support and (for many) a return to office based working, businesses are now looking to implement crucial plans and processes to manage their workforce in a fair, legal and responsible way.

Approximately one million companies have recently furloughed staff and are now weaning themselves off the Government’s Coronavirus Job Retention Scheme, which will come to an end on 31 October 2020. Given redundancy consultations in some instances can require a minimum of 30 days and up to 45 days, it is crucial companies who plan to cut jobs start the process in good time.

Dragon Argent’s experts Christine Slevin – Employment Solicitor, and James Taylor – Chief Commercial Officer, joined us to provide an update on some of the key considerations, risks and opportunities for employers as they navigate the second half of 2020.

Key questions covered included:
What is the correct procedure for making redundancies?
What should the employer and employee discuss at an individual redundancy consultation meeting?
In which redundancy situation will it not be necessary to determine a redundancy selection pool?
Is an employer obliged to wait a certain period of time before re-employing an employee who was dismissed for redundancy?

Should you have any questions for the Dragon Argent team, you can contact them directly:
James Taylor
james.taylor@dragonargent.com

Previous Post
HOW TO BUILD AND SUSTAIN A STRONG, RESILIENT BUSINESS
Next Post
VENTURE BOARD EFFECTIVENESS: THE RELATIONSHIP BETWEEN BOARDS AND VENTURE GROWTH

Latest News

Recap of our recent Neuroscience Investor Event

We’re excited to share some highlights from our recent Neuroscience Investor Event with Nevrargenics Ltd. The event, held on April 9th, 2024, was a fantastic gathering of business professionals, investors,…
Read more

Featured Events

Neuroscience Company Presentation

Tuesday

9 April 2024

The issue: Neurodegenerative diseases affect over a billion people worldwide; the human and economic cost of diseases like Fronto Temporal Dementia, Motor Neurone Disease (ALS, MND), Alzheimer’s, Parkinson’s and MS…
Read more
keyboard_arrow_up